2025-03-29 13:23:12
Latest Post
Cineline India Ltd monetizes Hotel Asset for INR 270 crores, becomes Net Debt-Free company
Emami Realty Limited appoints Ms. Ishani Ray as additional director
The Ramco Cements Ltd increases cement grinding capacity by 0.4 MTPA
Manappuram Finance Limited board approves fund raising program for FY 2025-26
Adani Renewable Energy Fifty Seven Ltd commissions incremental solar power project of 37.50 MW at Khavda
Stock Report
Rossari Biotech Ltd posts rise in consolidated PAT to Rs. 28.97 crores in Q4FY23
Posted On : 2023-04-29 17:26:02( TIMEZONE : IST )
Rossari Biotech Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 409.272 crores during the period ended March 31, 2023 as compared to Rs. 390.383 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 28.979 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 25.681 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 5.24 for the period ended March 31, 2023 as compared to Rs. 4.63 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹409.272 crs | ₹390.383 crs |  4.84% |
| Net Profit | ₹28.979 crs | ₹25.681 crs | 12.84% |
| EPS | ₹5.24 | ₹4.63 | 13.17% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.409.272 crores during the period ended March 31, 2023 as compared to Rs.440.904 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.28.979 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.24.081 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.5.24 for the period ended March 31, 2023 as compared to Rs.4.35 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹409.272 crs | ₹440.904 crs |  -7.17% |
| Net Profit | ₹28.979 crs | ₹24.081 crs | 20.34% |
| EPS | ₹5.24 | ₹4.35 | 20.46% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.1661.365 crores during the Financial Year ended March 31, 2023 as compared to Rs.1494.97 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.107.257 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.97.674 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.19.38 for the Financial Year ended March 31, 2023 as compared to Rs.17.70 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹1661.365 crs | ₹1494.97 crs | 11.13% |
| Net Profit | ₹107.257 crs | ₹97.674 crs | 9.81% |
| EPS | ₹19.38 | ₹17.70 | 9.49% |
Shares of Rossari Biotech Limited was last trading in BSE at Rs. 688.40 as compared to the previous close of Rs. 678.50. The total number of shares traded during the day was 10676 in over 1147 trades.
The stock hit an intraday high of Rs. 696.30 and intraday low of 677.65. The net turnover during the day was Rs. 7327846.00.
